EFPIA On How To Prepare EU For Future Health Crises
Lessons Need To Be Learned From COVID-19
Executive Summary
A report from industry federation EFPIA and its Vaccines Europe arm says that R&D has produced safe and effective tools for tackling COVID-19 but that the EU needs to address a set of short- to medium-term priorities if it is to be in a position to tackle future health emergencies.
You may also be interested in...
EMA Reviewing Bavarian Nordic’s Imvanex For Vaccination Against Monkeypox
EU member state authorities have been told they can use Jynneos, the US version of Bavarian Nordic’s smallpox vaccine, for the prevention of monkeypox. The bloc is also buying some 110,000 doses of the vaccine, with deliveries expected to begin shortly.
EU Bodies Agree Clearer Rules On Joint Procurement Of Vaccines & Treatments
The new regulation on cross-border threats to health is the final part of the European Health Union, along with strengthened roles for the European Medicines Agency and the European Centre for Disease Prevention and Control. Its aim is to ensure collective EU action on preparedness, surveillance, risk assessment, and early warning and response in the event of health emergencies.
International Regulators Plan Roadmap For Collaborative RWE Studies
Experiences during the COVID-19 pandemic are expected to help identify future opportunities for regulatory cooperation on real-world evidence and avoid divergent decision-making for products including advanced therapies and personalized medicines.